Press Releases
| Viewing Latest: 10 | Show: 25 | 50 | All (17) |
06 04 08
Algodon Wine Estates to present at Food & Wine Classic in Aspen >>
Algodon Wine Estates will be showcasing wine & pre-sale homesites at this year's Food & Wine Classic in Aspen, Colorado from June 13-15. This annual event is widely recognized and respected with over 5,000 attendees year after year.
05 16 08
Major Expansion Approved for Vineyard Resort Development in Mendoza, Argentina >>
The municipality of San Rafael, Mendoza, Argentina, has approved a major expansion plan for Algodon Wine Estates, a winery and luxury resort property in Argentina's scenic wine country. The announcement was made by Scott Mathis, Chairman of the property's developer and owner, InvestProperty Group, LLC (IPG Global Properties).
04 21 08
Viñas del Golf in San Rafael, Mendoza is Re-Branded Algodon Wine Estates >>
InvestProperty Group, LLC (IPG) and its Argentine luxury brand, Algodon, have acquired a stake in Viñas del Golf, a well-known wine brand and wine estate property in San Rafael, Mendoza, Argentina. Viñas del Golf was founded and developed by Ricardo Jurado, grandson of celebrated golfer José Jurado, who famously lost the British Open by one stroke in 1931.
03 18 08
InvestProperty Group, LLC Raises $11 Million From Accredited Investors to Participate in Institutional-Quality Real Estate Investments in Argentina >>
Firm is Developing Luxury Hotel in Buenos Aires and Winery and Golf Resort in Mendoza; Properties Will Carry Algodon Brand Name. NEW YORK CITY (March 19, 2008) - InvestProperty Group has raised over $11 million from accredited investors. InvestProperty Group allows individual accredited investors to diversify from the U.S. market by participating in institutional-quality real estate investments in Argentina, and capitalizing on an emerging market.
02 29 08
InvestBio Portfolio Company Presents Phase I/II Trial Results of Vaccine for Leukemia at American Society of Hematology Annual Meeting >>
To Date, InvestBio has Raised $20 Million for The Vaccine Company (TVC); TVC Now in Phase III Trials. NEW YORK CITY – February 29, 2008 – Results from a clinical study using technology licensed by The Vaccine Company (TVC), an InvestBio, Inc. portfolio company, were presented at the 49th Annual Meeting of the American Society of Hematology.
02 26 08
InvestBio Portfolio Company AmpliMed Corporation Announces Promising One-Year Survival Data >>
Data from Phase I/II Study of Amplimexon® in Treatment of Metastatic Malignant Melanoma. NEW YORK CITY - February 26, 2008 - AmpliMed Corporation, an InvestBio, Inc. portfolio company, recently announced one year survival results of Phase I/II trials of Amplimexon, its lead drug candidate in treating stage III or stage IV metastatic malignant melanoma (in combination with dacarbazine).
01 23 08
DPEC Partners Chairman Scott Mathis Joins Board of Kinexis, Inc. >>
NEW YORK CITY – January 23, 2008 – Scott Mathis, founder and chairman of Diversified Private Equity Corp. (DPEC), known as DPEC Partners, has been elected to the board of directors of Kinexis, Inc., a life sciences and R&D company that targets proteins that may be able to help treat neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
01 17 08
Former Group Publisher of ForbesLife Joins Diversified Private Equity Corp. (DPEC Partners) >>
Jack Laschever Joins Firm as Senior Managing Director of Venture Capital
NEW YORK CITY – January 17, 2008 –Scott L. Mathis, Chairman and Founder of Diversified Private Equity Corp. (DPEC Partners) announced today that Jack Laschever is joining the firm as a Senior Managing Director of Venture Capital.
01 08 08
Diversified Biotech Holdings Corp. Changes Name to Diversified Private Equity Corp. (DPEC Partners) >>
Change Reflects Updated Strategy to Bring Entrepreneurial and Institutional-Quality Investment Opportunities to Accredited Investors
NEW YORK CITY – January 8, 2008 – Diversified Biotech Holdings Corp. has changed its name to Diversified Private Equity Corp (DPEC Partners). DPEC, to be known as DPEC Partners, is an integrated company whose businesses bring entrepreneurial, private equity and institutional-quality investments to accredited individual investors.
01 03 08
AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon® in Metastatic Malignant Melanoma >>
AmpliMed today reported one year survival results from a Phase I/II trial of its lead drug candidate, Amplimexon® (imexon for injection) in combination with dacarbazine in patients with unresectable stage III or stage IV metastatic malignant melanoma. Results from the full cohort of patients in both the Phase I and Phase II shows a 11.7 month overall mean survival for the entire patient set and a 22 month overall mean survival in the subset of patients with normal LDH levels. This compares favorably to historical controls of 8 months and 10 months, respectively, for patients treated with dacarbazine alone.